Company page

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, trading under the ticker ABUS, is a public company based in the United States with a market capitalization of approximately $865 million. The company focuses on developing innovative therapies for the treatment of viral infections, particularly hepatitis B. Arbutus is committed to advancing its research and development efforts to address unmet medical needs in this area.